| Metric | Value ($ M) | vs Q2 FY25 |
|---|---|---|
| Revenue | 1.19 | 44.1% |
| Total Income | 1.19 | 44.1% |
| Expenditure | 4.67 | 17.4% |
| PBT | -10.43 | 55.2% |
| Net Profit | -10.43 | 55.2% |
| OPM | — | |
| NPM | — | |
| EPS | -0.19 |
Picard Medical Reports Q3 2025 Revenue Up 35% to $1.19 Million
04 May 2026 · 4 May, 7:09 am
Summary
Picard Medical announced financial results for the three and nine months ended September 30, 2025. Third quarter revenue reached $1.19 million, a 35 percent increase from the third quarter of 2024. The company completed its IPO on September 2, 2025, raising approximately $19.5 million in gross proceeds. For the nine-month period ending September 30, 2025, revenue totaled $3.93 million, up 11 percent from 2024. Operating loss narrowed to $3.36 million, compared to $3.77 million in the third quarter of 2024.
Key Highlights
- 1
Picard Medical's third quarter revenue reached $1.19 million, a 35 percent increase from the third quarter of 2024.
- 2
The company completed its IPO on September 2, 2025, raising approximately $19.5 million in gross proceeds.
- 3
Cost of revenue declined 15 percent year-over-year, reducing the gross loss by 81 percent to $0.13 million.
- 4
Operating loss narrowed to $3.36 million, compared to $3.77 million in the third quarter of 2024.
- 5
For the nine-month period ending September 30, 2025, revenue totaled $3.93 million, up 11 percent from 2024.
- 6
The company strengthened its intellectual-property portfolio with the issuance of U.S. Patent No. 12,383,722 B2.
- 7
Picard appointed independent directors Sam Van and George Ye to its Board of Directors on September 10th.
Management Comments
Patrick NJ Schnegelsberg
“The third quarter marked a pivotal moment for the company with the successful completion of its initial public offering in September. The IPO strengthened the balance sheet by retiring convertible debt, providing new capital to accelerate research, development, and commercial expansion across SynCardia’s life-saving artificial heart platform.” “In the third quarter, we continued to secure additional patent protection, underscoring our commitment to the life-saving technology around our SynCardia Total Artificial Heart, or STAH, the most widely used and extensively studied artificial heart in the world. We also welcomed Sam Van and George Ye to our board; both of whom have deep leadership experience in complementary areas to advise the company in its next stage as a public company.”
Informational and educational content only. Not investment advice.